British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK plc announced the completion of its previously announced acquisition of efimosfermin alfa from Boston Pharmaceuticals. Efimosfermin is a phase III-ready, potential best-in-class investigational ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal.

Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver ...

Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic ...

Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed. Among 65 ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma therapy approval.